At first, we evaluated the expression levels of CD44 in control cells (HPR1 and BPH) and prostate cancer cells derived from bone (PC3), lymph node (LNCaP) and brain (DU145) metastases (Figure3A). This evidence concerns the gene CD44 and Familial prostate cancer.